Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Peek Into Korean Bioventures’ Success Factors, Challenges

Executive Summary

Amid a boom in IPOs and valuations, experts at a recent forum in Seoul took a look at some of the success factors and challenges behind the rapid growth of South Korea’s bioventure sector.

You may also be interested in...



New Funding To Give ViroMed ‘Favorable Position’ For Gene Therapy Deal

ViroMed joins a group of South Korean bioventures launching share offerings to fund R&D activities, in its case to beef up the clinical data package for its lead project VM202, which should in turn help with a licensing out deal for the gene therapy.

Bridge Bio Eyes Faster Pipeline Progress Through New Funds, Model

A Series A funding for South Korean bioventure Bridge Biotherapeutics may encourage creation of “no research, development only” bioventures and early investments in the biotech sector.

Genexine Raises New Funds To Progress Promising HPV, Other Projects

South Korean bioventure Genexine is on track to meet its goal of progressing and expanding this year the clinical development of its leading assets - orphan disease drugs and cancer immunotherapies. The company now plans to raise new funds via share and bond issues to domestic and overseas investors including its Chinese strategic alliance partner Tasly.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC096956

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel